Prime Medicine reported victory in an arbitration dispute with Beam Therapeutics over gene-editing technology tied to an alpha-1 antitrypsin deficiency (AATD) program. Arbitrators determined Prime’s work did not violate a 2019 agreement that was intended to prevent the two companies from competing against one another. Prime said the ruling clears the path to begin a clinical trial for AATD “this quarter,” while the outcome represents a setback for Beam. The dispute highlights how platform and licensing terms continue to shape timelines for gene-editing pipelines, even as scientific progress accelerates. The decision also lifted Prime’s stock after the ruling, underscoring market sensitivity to program continuity in editing-led franchises.